Mal-(CH2)5-Val-Cit-PAB-Eribulin is an agent-linker conjugate designed for antibody-drug conjugates (ADCs) and demonstrates robust antitumor activity. It incorporates the anti-microtubule agent Eribulin, which is employed in the study of metastatic breast cancer.
Usually ships within 24 hours.